PMID- 17474121
OWN - NLM
STAT- MEDLINE
DCOM- 20070716
LR  - 20071203
IS  - 0008-543X (Print)
IS  - 0008-543X (Linking)
VI  - 111
IP  - 3
DP  - 2007 Jun 25
TI  - Fluorescence in situ hybridization of ductal lavage samples identifies malignant 
      phenotypes from cytologically normal cells in women with breast cancer.
PG  - 185-91
AB  - BACKGROUND: Ductal lavage (DL) does not routinely identify cytologically 
      malignant cells. For this study, the authors asked whether molecular analyses of 
      DL specimens from women with cancer would identify abnormal cells, even if they 
      appeared cytologically normal. METHODS: DL was performed and yielded fluid in 29 
      of 45 consenting women who were undergoing breast cancer surgery. Array 
      comparative genomic hybridization (CGH) was performed on the corresponding tumor 
      tissue from 14 women. There was no single, common alteration; thus, bacterial 
      artificial chromosome-specific fluorescence in situ hybridization (FISH) probes 
      were selected based on CGH alterations. RESULTS: FISH copy number changes were 
      detected in tumor sections in 9 women. In the corresponding 9 DL samples, 1 
      sample was clearly malignant on cytology, 1 showed marked atypia, 1 showed mild 
      atypia, and the rest were benign. Five of the 9 DL samples had epithelial cells 
      that showed genetic changes identical to those observed in the tumor by FISH. The 
      remaining 4 of 9 DL samples that did not show molecular changes were probably (N 
      = 1) or possibly (N = 3) from the same duct as the tumor. CONCLUSIONS: Although 
      only 11% of the DL samples were identified as malignant cytologically, 55% showed 
      molecular changes that were identical to those observed in the tumor. FISH was 
      more sensitive for finding tumor in DL specimens than cytology. However, the 
      ductal system in which the tumor was located did not always yield fluid, limiting 
      the sensitivity of DL. The results from this study showed that genetic changes 
      can be detected in the absence of morphologic changes in cytologically benign 
      cells, but the application will be limited without a better approach for 
      acquiring cells and a common set of probes for detecting molecular abnormalities 
      that are found in breast malignancies.
FAU - Adduci, Kelly M
AU  - Adduci KM
AD  - Department of Surgery, University of California San Francisco, San Francisco, CA 
      94143-0808, USA.
FAU - Annis, Caroline E
AU  - Annis CE
FAU - DeVries, Sandy
AU  - DeVries S
FAU - Chew, Karen L
AU  - Chew KL
FAU - Boutin, Jennifer
AU  - Boutin J
FAU - Magrane, Gregg
AU  - Magrane G
FAU - Ljung, Britt-Marie
AU  - Ljung BM
FAU - Waldman, Frederic M
AU  - Waldman FM
FAU - Esserman, Laura J
AU  - Esserman LJ
LA  - eng
GR  - P50 CA58207/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer
JT  - Cancer
JID - 0374236
SB  - IM
MH  - Biopsy, Needle
MH  - Breast/metabolism/pathology
MH  - Breast Neoplasms/genetics/*pathology
MH  - Carcinoma, Ductal, Breast/genetics/*pathology
MH  - Cytodiagnosis/instrumentation/methods
MH  - Female
MH  - Genome, Human
MH  - Humans
MH  - In Situ Hybridization, Fluorescence/*methods
MH  - Middle Aged
MH  - Nucleic Acid Hybridization/methods
MH  - Phenotype
MH  - Reproducibility of Results
EDAT- 2007/05/03 09:00
MHDA- 2007/07/17 09:00
CRDT- 2007/05/03 09:00
PHST- 2007/05/03 09:00 [pubmed]
PHST- 2007/07/17 09:00 [medline]
PHST- 2007/05/03 09:00 [entrez]
AID - 10.1002/cncr.22690 [doi]
PST - ppublish
SO  - Cancer. 2007 Jun 25;111(3):185-91. doi: 10.1002/cncr.22690.